The Garden of Hope provides cancer survivors with access to fresh produce and a supportive community, bridging clinical ...

Key FDA action dates in early 2026 promise to transform treatment options for solid tumors and rare hematologic malignancies, ...

For centuries, the field of pathology has been defined by a single instrument: the microscope. But according to William ...

On August 8, 2025, the FDA granted accelerated approval to zongertinib for adult patients with unresectable or metastatic ...

Discover the latest breakthroughs in multiple myeloma treatment, including CAR T-cell therapies and promising new options for ...

In July, the FDA issued a complete response letter (CRL) for Replimune's biologics license application for RP1 (vusolimogene ...

A study published earlier this year in the Journal of Neuro-Oncology indicates that sonodynamic therapy (SDT) safely destroys GBM cells while preserving healthy brain tissue. Using a noninvasive ...

While the current approval focuses on the second-line setting, research is already moving into earlier stages of the ...

Here are the top 5 articles detailing the advancements in hematologic oncology from 2025. BTK inhibitors have revolutionized ...

The US FDA has approved mosunetuzumab-axgb (Lunsumio VELO) as a subcutaneous formulation for the treatment of adult patients ...

Luveltamab tazevibulin, a novel ADC, showed encouraging responses in platinum-resistant ovarian cancer, with a 32% ORR and a ...

In this segment, Dr Luskin examines how patient-related factors influence treatment decisions in blastic plasmacytoid ...